China's Drug Regulator Deepens Approval Reform to Boost Pharmaceutical Innovation on May 25

GateNews
On May 25, China's National Medical Products Administration (NMPA) held a leadership meeting chaired by Party Chief and Director Huang Guo to emphasize pharmaceutical policy reform. The meeting stressed three priorities: reinforcing drug safety standards, innovating approval and review processes to accelerate pharmaceutical innovation, and improving oversight systems. NMPA aims to deepen regulatory reform to enhance industry competitiveness while maintaining strict safety compliance.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments